Dem bill would undo big lobbying win for drug maker Amgen

ADVERTISEMENT
"Without scrutiny or debate, the American taxpayer was stuck with the $500 million tab," Welch said in a statement. "This special interest provision should have stood on its own merits with an up or down vote. It’s no wonder cockroaches and root canals are more popular than Congress.”